Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(14%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_4
2
29%
Ph phase_2
2
29%
Ph phase_3
2
29%
Ph early_phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(3)

Detailed Status

Completed3
Enrolling by invitation2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 42 (28.6%)

Trials by Status

enrolling_by_invitation229%
not_yet_recruiting114%
completed343%
recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
enrolling_by_invitationearly_phase_1

Tapinarof for Cutaneous Lupus Erythematosus

NCT06661213
recruitingphase_2

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

NCT06561321
not_yet_recruitingphase_4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
enrolling_by_invitationphase_2

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

NCT05981118
completedphase_3

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

NCT03983980
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06661213Early Phase 1

Tapinarof for Cutaneous Lupus Erythematosus

Enrolling By Invitation
NCT06561321Phase 2

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

Recruiting
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT05981118Phase 2

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

Enrolling By Invitation
NCT03983980Phase 3

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Completed
NCT03956355Phase 3

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Completed
NCT06103695Phase 4

Vtama in Psoriasis Patients Being Treated With Biologics.

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7